Combination therapy with inhaled glucocorticosteroids/long-acting beta-agonists in patients with bronchial asthma: choice of the best possible in real clinical practice


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The basis for the treatment of bronchial asthma (BA) includes inhaled glucocorticosteroids (IGCS), usually in combination with long-acting fc-adrenoagonists (LABA) - IGCS/LABA. As this group of drugs becomes more and more representative over time, the practitioner often faces a difficult question about choosing the “best possible". The main tool of evidence-based medicine is randomized clinical trials (RCTs), which do not always reflect real clinical practice. To this extent, the so-called pragmatic RCTs have no such disadvantage. One of them, the Salford Lung Study (SLS) is a 12-month phase III study to evaluate the efficacy and safety of the new combination drug containing modern IGCS fluticasone furoate (FF) and LABA vilanterol (VI) - 100 μg/25 μg or 200 μg/25 μg given once a day in the form of a multi-dose dry powder inhaler [23]. During the SLS, the therapeutic superiority of FF/VI over “conventional therapy" in achieving asthma control was demonstrated, and it was attributable to the clinical pharmacology features of the new combination of IGCS+LABA, including possibility of taking the drug once a day.

全文:

受限制的访问

作者简介

A. Sinopalnikov

Russian Medical Academy of Continuous Professional Education

Email: aisyn@list.ru
MD, Professor., Head of the Department of Pulmonology

参考

  1. Global Asthma Report (December 14, 2017). Available from: http://www.globalasthmareport. org/resources/ Global_Asthma_ Report_ 2017. pdf.
  2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2019. Available from://ginasthma.org/.
  3. Hekking PP, Bel E.H. Developing and emerging clinical asthma phenotypes. J Allergy Clin Immunol Pract. 2014;2:671-80. Doi: 10.1016/j. jaip.2014.09.007.
  4. Papi A., Brightling C., Pedersen S.E., Reddel H.K. Asthma. Lancet. 2018;391:783-800. doi: 10.1016/S0140-6736(17)33311-1.
  5. Howard R., Rattray M., Prosperi M., Custovic A. Distinguishing Asthma Phenotypes Using Machine Learning Approaches. Curr Allergy Asthma Rep. 2015;15-38. doi: 10.1007/s11882-015-0542-0.
  6. Skloot G.S. Asthma phenotypes and endotypes: a personalized approach to treatment. Curr Opin Pulm Med. 2016;22:3-9. Doi: 10.1097/ MCP0000000000000225.
  7. Kola I., Bell J. A call to reform the taxonomy of human disease. Nature reviews Drug discovery. 2011;10:641-42. doi: 10.1038/nrd3534.
  8. Barnes P.J. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J. 2002;19:189-91.
  9. Heddini A, Sundh J., Ekstrom M., Janson C. Effectiveness trials: critical data to help understand how respiratory medicines really work? Eur Clin Respir J. 2919l6:1565994. doi: 10.1090/20019525.2019.1565904.
  10. Burns PB, Rohrich R.J., Chung K.C. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128:305-10. doi: 10.1097/PRS.0b013e318219c171.
  11. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2018. Available from: //ginasthma.org/
  12. Treweek S., Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2999;19-37. doi: 10.1186/1745-6215-10-37.
  13. Herland K., Akselsen J.P, Skj0nsberg O.H., et al. How representative are clinical study patients with asthma or COPD for a lager«real life» population of patients with obstructive lung disease? Respir Med. 2005;99:11-9.
  14. Lisspers K., Teixeira P, Blom C., et al. Are pharmacological randomized controlled clinical trials relevant to real-life asthma populations? A protocol for an UNLOCK study from the IPCRG. NPJ Prim Care Respir Med. 2016;26:16016. doi: 10.1038/npjpcrm.2016.16.
  15. Covvey J.R., Mullen A.B., Ryan M., et al. A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom. Int J Clin Pract. 2014;68:1200-1208. doi: 10.1111/ijcp.12451.
  16. Rolnick S.J., Pawloski PA., Hedblom B.D., et al. Patient characteristics associated with medication adherence. Clin Med Res. 2913;11:54-65. doi: 10.3121/cmr.2013.1113.
  17. Vergresson N. Thalidomide-induced teratogenesis: history and mechanisms. Brith Defects res C Embryo Today. 2015;105:140-56. Doi: 10.1002/ bdrc.21096.
  18. lenz W. Thalidomide embryopathy in Germany, 1959-1961. Prog Clin Biol Res. 1985; 163:77-83.
  19. Ridings J.E. The thalidomide disaster, lessons from the past. Methods Mol Biol. 2013;947575-586. doi: 10.1007/978-1-62703-131-8_36.
  20. New J.P, Bakerly N.D., Leather D., Woodcock A. Obtaining real-world evidence: the Salford Lung Study. Thorax. 2914;69:1152-54. Doi: 19.1136/ thoraxjnl-2014-205259.
  21. Roche N., Reddel H.K., Agusti A., et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med. 2013;1:29-30. doi: 10.1016/S2213-2600(13)70199-1.
  22. Chalkidou K., Tunis S., Whicher D., et al. The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research. Clin Trials. 2912;9:436-46. doi: 10.1177/1740774512450097.
  23. Woodcock A., Bakerly N.D., New J.P, et al. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma. BMC Pulm Med. 2015;15:160. doi: 10.1186/s12890-015-0150-8.
  24. Nathan R.A., Sorkness M., Kosinski M., et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59-65.
  25. Kosinski M., Kite A., Yang M., et al. Comparability of the Asthma Control Test telephone interview administration format with self-administered mail-out mail-back format. Curr Med Res Opin. 2009;25:717-27.
  26. Schatz M., Kosinski M., Yarlas A.S., et al. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2999;124:719-23. Doi: 10.1016/j. jaci.2009.06.053.
  27. Woodcock A., Vestbo J., Bakerly N.D., et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomized controlled trial. Lancet. 2017;390:2247-55. Doi: 10.1016/ S0140-6736(17)32397-8.
  28. Svedsater H., Jones R., Bosanquet N., et al. Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. Respir Med. 2018;141:198-206. Doi: 10.1016/j. rmed.2018.06.003.
  29. Juniper E.F., Guyatt G.H., Ferrie PJ., Griffith L.E. Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147;832-38.
  30. Juniper E.F., Buist A.S., Cox F.M., et al. Validation of a standardized version of the asthma quality of life questionnaire. Chest. 1999;115:1265-70.
  31. The EuroQol Group, EuroQol - a new facility for the measurement of health-related quality of life. Health Pol. 1990;16:199-208.
  32. Reilly M.C., Zbrozek A.S., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353-65.
  33. Travers J., Marsh S., Williams M., et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax. 2007;62:219-23.
  34. Price D., Chisholm A., van der Molen T., et al. Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. Curr Allergy Asthma Rep. 2011;11:526-38. Doi: 10.1007/ s11882-011-0222-7.
  35. Bonora M., Wieckowsk M.R., Chinopoulos C., et al. Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. Oncogene. 2015;34(12):1608. Doi: 10.1038/ onc.2014.462.
  36. Van der Palen J., Thomas M., Chrystyn H., et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016;26:16079. doi: 10.1038/npjpcrm.2016.79.
  37. Kerwin E.M., Preece A., Brintziki D., et al. ELLIPTA Dry Powder Versus Metered-Dose Inhalers in an Optimized Clinical Trial Setting. J Allergy Clin Immunol Pract 2019;7:1843-49. doi: 10.1016/j.jaip.2019.02.023

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2019
##common.cookie##